Hutch Integrated Data Repository and Archive

Areas of focus

Key Features

  • A secure and extensible data "pipeline" to collect,
    move and store clinical records, patients' stories and
    clinical histories with related biospecimens. 
  • Natural language processing algorithms to extract
    important data elements from electronic medical records.
  • Enterprise-wide tracking of consent and study information so patient data confidentiality is maintained.
  • The ability to index and search across clinical and research data using HIDRA and access other relevant data from across the entire cancer center.

Hutch Integrated Data Repository and Archive (HIDRA) is a collaborative effort of the Fred Hutch/University of Washington Cancer Consortium. The goal is to create a database that will enable scientists and physicians to learn from every new patient who comes through the door. Using data from historical and new cases will enable scientists to translate and integrate that knowledge into clinical care through new trials and patient care. 

More than just an oncology data warehouse

HIDRA is intended to be more than a data warehouse.  Currently limited to Cancer Consortium partner data, the secure database is based on open-source, freely-licensed LabKey Software that potentially could become available to the entire biomedical community.  It will also save money as we expand by using natural language processing to help automate manual data abstraction and processing of medical records.

Paul Fearn

Paul Fearn, Biomedical Informatics Lead

Photo by Robert Hood

HIDRA, when completed, will be able to combine every kind of data at the center - from information written by clinicians to the molecular data that geneticists pull from tissue samples. Scientists will have the ability to query information from clinical records and treatment outcomes from thousands for patients.

"Historically we treated cancers by the part of the body affected but now we're classifying cancer molecularly," said Paul Fearn, biomedical informatics lead at Fred Hutch. "There could be several cancers related to one genetic variation. Now, imagine being able to look across every single instance of an expressed gene in every single person who's come through the door.  That would be the holy grail of precision oncology.  That's what HIDRA is intended to be."

The HIDRA project involves ongoing collaboration with our partners, including Solid Tumor Translational Research (STTR), Seattle Cancer Care Alliance (SCCA), UW Medicine, Seattle Children’s and LabKey Software. HIDRA portals for multiple cancers will be released in 2015.